CpG-ODN attenuates pathological cardiac hypertrophy and heart failure by activation of PI3Kα-Akt signaling.

CpG-ODN attenuates pathological cardiac hypertrophy and heart failure by activation of PI3Kα-Akt signaling.

Phosphoinositide-3-kinase α (PI3Kα) represents a potential novel drug target for pathological cardiac hypertrophy (PCH) and heart failure. Oligodeoxynucleotides containing CpG motifs (CpG-ODN) are classic agonists of Toll-like receptor 9 (TLR9), which typically activates PI3K-Akt signaling in immune...

Full description

Bibliographic Details
Main Authors: Liang Yang, Xiangyu Cai, Jie Liu, Zhe Jia, Jinjin Jiao, Jincai Zhang, Changlin Li, Jing Li, Xiang D Tang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3640052?pdf=render

Internet

http://europepmc.org/articles/PMC3640052?pdf=render

Similar Items